Evidence map›Paper›PMID 35411097›Full record

ArticleLeukemia2022

Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis Kourelis and 6 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Alissa VisramDivision of Hematology, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID http://orcid.org/0000-0002-7201-4642
S Vincent RajkumarDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4342-364X
Angela DispenzieriDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8780-9512
Martha Q LacyDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Morie A GertzDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Francis K BuadiDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3214-0203
Suzanne R HaymanDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
David DingliDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7477-3004
Taxiarchis KourelisDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8573-9434
Wilson GonsalvesDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Rahma WarsameDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Eli MuchtarDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2210-2174
Nelson LeungDivision of Nephrology, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5651-1411
Robert A KyleDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Shaji K KumarDivision of Hematology, Mayo Clinic Rochester, Rochester, MN, USA. kumar.shaji@mayo.edu.ORCID http://orcid.org/0000-0001-5392-9284

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35411097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.